LLY: Multiplikator rega marang pendapatan Lilly

The price-to-sales ratio reflects the business valuation trend, where the 15.70 level represents the current value. Eli Lilly and Company (LLY) is implementing green technologies in its laboratories to reduce emissions. Stability is supported by successful tests of new drugs and patent protection. However, price controls and the expiration of exclusive rights for key medications create risks.

The P/S multiple determines the market value of a business relative to its annual revenue, allowing an investor to assess the degree of overpayment per unit of sales. Fundamental P/S analysis demonstrates how explosive demand for innovative diabetes medications and the patent-protected R&D of Eli Lilly and Company (LLY) justify a high sales premium, turning local dips in the ratio into an entry point while long-term competitive advantages persist.